Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bundibugyo virus vaccine study in contacts of confirmed cases in the Democratic Republic of the Congo
PACTR202611537299433Phase 3Not yet recruiting
- Sponsor
- University of Antwerp
- Start
- Nov 2026
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of salmonella typhi capsular polysaccharide vaccine in Bundibugyo ebolavirus infection (BDBV) and Ebola virus disease (EVD) (2 arms), sponsored by University of Antwerp. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
salmonella typhi capsular polysaccharide vaccine
03
Conditions
Bundibugyo ebolavirus infection (BDBV)Ebola virus disease (EVD)
Beyond the preview
Go deeper on PACTR202611537299433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202611537299433.